Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.71
+1.02 (6.11%)
At close: Mar 23, 2026, 4:00 PM EDT
17.81
+0.10 (0.56%)
After-hours: Mar 23, 2026, 7:45 PM EDT

Sarepta Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-713.41235.24-535.98-703.49-418.78
Depreciation & Amortization
44.5217.2917.0441.8638.02
Stock-Based Compensation
5037.72182.51233.02113.94
Other Adjustments
203.53184.52518.13146.23-78.19
Change in Receivables
203.76-201.66-185.7-61.64-51.65
Changes in Inventories
-301.09-395.17-147.71-50.78-83.77
Changes in Accounts Payable
104.27110.65-50.14147.5723.3
Changes in Unearned Revenue
72.05-32.16-86.83-89.24-89.24
Changes in Other Operating Activities
-0.94-198.26-10.7115103.2
Operating Cash Flow
-205.48-205.79-500.99-325.35-443.17
Capital Expenditures
-101.97-136.96-76.11-30.82-38.49
Purchases of Intangible Assets
-7.88-10-11.24-1.43-2.31
Proceeds from Sale of Intangible Assets
--102-102
Purchases of Investments
-290.48-1,104-2,045-1,938-31.79
Proceeds from Sale of Investments
295.872,1761,868923.22466
Investing Cash Flow
69.64755.56-165.8-1,047495.41
Long-Term Debt Issued
---1,127-
Long-Term Debt Repaid
-158.42--0.07-797.87-
Net Long-Term Debt Issued (Repaid)
-158.42--0.07329.53-
Issuance of Common Stock
38.779.5351.2530.04569.33
Repurchase of Common Stock
-25.01----7.77
Net Common Stock Issued (Repurchased)
13.6979.5351.2530.04561.57
Other Financing Activities
-23.6245.3573.76-127.07-
Financing Cash Flow
-168.34124.81125232.51561.57
Net Cash Flow
-304.18674.58-541.79-1,140613.81
Free Cash Flow
-307.45-342.74-577.1-356.17-481.66
FCF Margin
-13.99%-18.02%-46.42%-38.17%-68.62%
Free Cash Flow Per Share
-3.07-3.18-6.25-4.07-5.93
Levered Free Cash Flow
-1,055-399.37-890.5-340.37-465.77
Unlevered Free Cash Flow
-894.1-437.88-630.46-513.12-506.51
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q